It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diffuse infiltration is the main reason for therapeutic resistance and recurrence in glioblastoma (GBM). However, potential targeted therapies for GBM stem-like cell (GSC) which is responsible for GBM invasion are limited. Herein, we report Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase like Orphan Receptor 1 (ROR1), as a promising target for GSC invasion. Using a GSC-derived brain tumor model, GSCs were characterized into invasive or non-invasive subtypes, and RNA sequencing analysis revealed that IGFBP5 was differentially expressed between these two subtypes. GSC invasion capacity was inhibited by IGFBP5 knockdown and enhanced by IGFBP5 overexpression both in vitro and in vivo, particularly in a patient-derived xenograft model. IGFBP5 binds to ROR1 and facilitates ROR1/HER2 heterodimer formation, followed by inducing CREB-mediated ETV5 and FBXW9 expression, thereby promoting GSC invasion and tumorigenesis. Importantly, using a tumor-specific targeting and penetrating nanocapsule-mediated delivery of CRISPR/Cas9-based IGFBP5 gene editing significantly suppressed GSC invasion and downstream gene expression, and prolonged the survival of orthotopic tumor-bearing mice. Collectively, our data reveal that IGFBP5-ROR1/HER2-CREB signaling axis as a potential GBM therapeutic target.
Glioblastoma stem-like cells (GSCs) contribute to therapeutic resistance and recurrence of glioblastomas. Here the authors show that Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) promotes GSCs invasion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); Ewha Womans University, Department of Life Science, Seoul, Republic of Korea (GRID:grid.255649.9) (ISNI:0000 0001 2171 7754)
2 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X)
3 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); Personalized Genomic Medicine Research Center, KRIBB, Daejeon, Republic of Korea (GRID:grid.249967.7) (ISNI:0000 0004 0636 3099)
4 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); Macquarie University, Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine & Health Sciences, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405)
5 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
6 National Cancer Center, Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
7 National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
8 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810); National Cancer Center, Research Institute, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
9 Henan University, Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Kaifeng, China (GRID:grid.256922.8) (ISNI:0000 0000 9139 560X); National Cancer Center, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)